Overview

Impact of Intrathecal vs Intravenous Dexmedetomidine

Status:
NOT_YET_RECRUITING
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this research is to evaluate the impact of intrathecal dexmedetomidine in comparison with intravenous route in patients undergoing cesarean section. Alternate hypothesis :Dexmedetomidine is more effective when given intrathecally as adjuvant to bupivacaine in elective cesarean section Null Hypothesis: Dexmedetomidine is more effective when given intravenously as adjuvant to bupivacaine in elective cesarean section Study Design: Randomized controlled trial Study setting: Watim General Hospital Study Duration: 18 months after synopsis approval Sampling technique: Simple random sampling Sample Size: Using the Open Epi program, a sample size of 60 patients (30 in each group) was determined with a 95% confidence interval and 80% power. Inclusion Criteria: * Pregnant women between ages 18-35 years * Belongs to ASA class I or II * Subjected to elective C-section Exclusion Criteria: * Any history of gastrointestinal disease diabetes, thyroid disease, hypertension, obesity, or anemia * History of alcohol or drug abuse; * Major complications of pregnancy * Patients have contraindication to spinal block or allergic to any of drug
Phase:
PHASE4
Details
Lead Sponsor:
Muhammad Ilyas
Treatments:
Bupivacaine
Dexmedetomidine